It is becoming more apparent that inflammatory processes represent a key driver of neurodegenerative diseases rather than acting as a bystander, with confirmation from genetic studies indicating many risk genes to be associated with inflammation and the innate immune response [6] including complement regulators like CLU, which encodes for clusterin, a weak negative regulator of membrane attack complex (MAC) assembly, and CR1, encoding for complement receptor 1 [7–9]. This evidence concerns the gene CLU and neurodegenerative disease.